AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TBPH
  4. [Form 4] Theravance Biopharma, Inc. Insider Trading Activity

[Form 4] Theravance Biopharma, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Rick E. Winningham, CEO and Director of Theravance Biopharma, reported a significant insider transaction on June 23, 2025. The executive made a bona fide gift of 20,000 ordinary shares with no compensation received.

Following the transaction, Winningham's holdings include:

  • 1,733,180 shares held directly
  • 13,500 shares held as custodian
  • 92,567 shares held in trust

The Form 4 filing indicates Winningham maintains substantial ownership in the company despite the gifted shares. The transaction was executed under regular conditions and was not part of a Rule 10b5-1 trading plan. The filing was completed through his attorney-in-fact, Brett A. Grimaud, on June 25, 2025.

Rick E. Winningham, CEO e Direttore di Theravance Biopharma, ha comunicato una significativa operazione interna il 23 giugno 2025. Il dirigente ha effettuato una donazione autentica di 20.000 azioni ordinarie senza ricevere alcun compenso.

A seguito dell'operazione, le partecipazioni di Winningham comprendono:

  • 1.733.180 azioni detenute direttamente
  • 13.500 azioni detenute come custode
  • 92.567 azioni detenute in trust

La dichiarazione Form 4 indica che Winningham mantiene una significativa propriet脿 nella societ脿 nonostante le azioni donate. L'operazione 猫 stata eseguita in condizioni ordinarie e non faceva parte di un piano di trading secondo la regola 10b5-1. La dichiarazione 猫 stata completata tramite il suo procuratore, Brett A. Grimaud, il 25 giugno 2025.

Rick E. Winningham, CEO y Director de Theravance Biopharma, inform贸 una transacci贸n interna significativa el 23 de junio de 2025. El ejecutivo realiz贸 un regalo leg铆timo de 20,000 acciones ordinarias sin recibir compensaci贸n alguna.

Tras la transacci贸n, las participaciones de Winningham incluyen:

  • 1,733,180 acciones en propiedad directa
  • 13,500 acciones en calidad de custodio
  • 92,567 acciones en fideicomiso

El formulario 4 indica que Winningham mantiene una participaci贸n considerable en la empresa a pesar de las acciones donadas. La operaci贸n se realiz贸 en condiciones normales y no form贸 parte de un plan de negociaci贸n bajo la regla 10b5-1. La presentaci贸n fue realizada a trav茅s de su apoderado, Brett A. Grimaud, el 25 de junio de 2025.

Rick E. Winningham, Theravance Biopharma鞚� CEO 瓴� 鞚挫偓搿滌劀 2025雲� 6鞗� 23鞚� 欷戩殧頃� 雮措秬鞛� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 鞛勳洂鞚� 氤挫儊 鞐嗢澊 20,000欤� 氤错喌欤�毳� 歆勳爼頃� 歃濎棳搿� 鞝滉车頄堨姷雼堧嫟.

瓯半灅 鞚错泟 Winningham鞚� 氤挫湢 欤检嫕鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 歆侅爲 氤挫湢 1,733,180欤�
  • 靾橅儊鞛愲靹� 氤挫湢 13,500欤�
  • 鞁犿儊鞙茧 氤挫湢 92,567欤�

Form 4 鞝滌稖靹滊鞐� 霐半ゴ氅�, 歃濎棳頃� 欤检嫕鞐愲弰 攵堦惮頃橁碃 Winningham鞚� 須岇偓鞐� 靸侂嫻頃� 歆�攵勳潉 鞙犾頃橁碃 鞛堨姷雼堧嫟. 瓯半灅電� 鞚茧皹鞝侅澑 臁瓣贝 頃橃棎 鞚措（鞏挫鞙茧┌ Rule 10b5-1 瓯半灅 瓿勴殟鞚� 鞚茧秬臧� 鞎勲媹鞐堨姷雼堧嫟. 鞝滌稖鞚� 2025雲� 6鞗� 25鞚� 攴胳潣 氩曥爼 雽�毽澑 Brett A. Grimaud毳� 韱淀暣 鞕勲霅橃棃鞀惦媹雼�.

Rick E. Winningham, PDG et Directeur de Theravance Biopharma, a d茅clar茅 une transaction d鈥檌niti茅 importante le 23 juin 2025. Le dirigeant a effectu茅 un don authentique de 20 000 actions ordinaires sans aucune contrepartie financi猫re.

Apr猫s la transaction, les participations de Winningham comprennent :

  • 1 733 180 actions d茅tenues directement
  • 13 500 actions d茅tenues en qualit茅 de d茅positaire
  • 92 567 actions d茅tenues en fiducie

Le d茅p么t du formulaire 4 indique que Winningham conserve une participation importante dans la soci茅t茅 malgr茅 les actions donn茅es. La transaction a 茅t茅 r茅alis茅e dans des conditions normales et ne faisait pas partie d鈥檜n plan de trading selon la r猫gle 10b5-1. Le d茅p么t a 茅t茅 effectu茅 par son mandataire, Brett A. Grimaud, le 25 juin 2025.

Rick E. Winningham, CEO und Direktor von Theravance Biopharma, meldete am 23. Juni 2025 eine bedeutende Insider-Transaktion. Der Gesch盲ftsf眉hrer t盲tigte eine echte Schenkung von 20.000 Stammaktien ohne jegliche Gegenleistung.

Nach der Transaktion umfasst Winninghams Beteiligung:

  • 1.733.180 Aktien im Direktbesitz
  • 13.500 Aktien als Treuh盲nder gehalten
  • 92.567 Aktien in einem Trust gehalten

Die Form 4 Einreichung zeigt, dass Winningham trotz der geschenkten Aktien eine erhebliche Beteiligung am Unternehmen beh盲lt. Die Transaktion wurde unter regul盲ren Bedingungen durchgef眉hrt und war kein Teil eines Rule 10b5-1 Handelsplans. Die Einreichung erfolgte am 25. Juni 2025 durch seinen Bevollm盲chtigten Brett A. Grimaud.

Positive
  • None.
Negative
  • None.

Rick E. Winningham, CEO e Direttore di Theravance Biopharma, ha comunicato una significativa operazione interna il 23 giugno 2025. Il dirigente ha effettuato una donazione autentica di 20.000 azioni ordinarie senza ricevere alcun compenso.

A seguito dell'operazione, le partecipazioni di Winningham comprendono:

  • 1.733.180 azioni detenute direttamente
  • 13.500 azioni detenute come custode
  • 92.567 azioni detenute in trust

La dichiarazione Form 4 indica che Winningham mantiene una significativa propriet脿 nella societ脿 nonostante le azioni donate. L'operazione 猫 stata eseguita in condizioni ordinarie e non faceva parte di un piano di trading secondo la regola 10b5-1. La dichiarazione 猫 stata completata tramite il suo procuratore, Brett A. Grimaud, il 25 giugno 2025.

Rick E. Winningham, CEO y Director de Theravance Biopharma, inform贸 una transacci贸n interna significativa el 23 de junio de 2025. El ejecutivo realiz贸 un regalo leg铆timo de 20,000 acciones ordinarias sin recibir compensaci贸n alguna.

Tras la transacci贸n, las participaciones de Winningham incluyen:

  • 1,733,180 acciones en propiedad directa
  • 13,500 acciones en calidad de custodio
  • 92,567 acciones en fideicomiso

El formulario 4 indica que Winningham mantiene una participaci贸n considerable en la empresa a pesar de las acciones donadas. La operaci贸n se realiz贸 en condiciones normales y no form贸 parte de un plan de negociaci贸n bajo la regla 10b5-1. La presentaci贸n fue realizada a trav茅s de su apoderado, Brett A. Grimaud, el 25 de junio de 2025.

Rick E. Winningham, Theravance Biopharma鞚� CEO 瓴� 鞚挫偓搿滌劀 2025雲� 6鞗� 23鞚� 欷戩殧頃� 雮措秬鞛� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 鞛勳洂鞚� 氤挫儊 鞐嗢澊 20,000欤� 氤错喌欤�毳� 歆勳爼頃� 歃濎棳搿� 鞝滉车頄堨姷雼堧嫟.

瓯半灅 鞚错泟 Winningham鞚� 氤挫湢 欤检嫕鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 歆侅爲 氤挫湢 1,733,180欤�
  • 靾橅儊鞛愲靹� 氤挫湢 13,500欤�
  • 鞁犿儊鞙茧 氤挫湢 92,567欤�

Form 4 鞝滌稖靹滊鞐� 霐半ゴ氅�, 歃濎棳頃� 欤检嫕鞐愲弰 攵堦惮頃橁碃 Winningham鞚� 須岇偓鞐� 靸侂嫻頃� 歆�攵勳潉 鞙犾頃橁碃 鞛堨姷雼堧嫟. 瓯半灅電� 鞚茧皹鞝侅澑 臁瓣贝 頃橃棎 鞚措（鞏挫鞙茧┌ Rule 10b5-1 瓯半灅 瓿勴殟鞚� 鞚茧秬臧� 鞎勲媹鞐堨姷雼堧嫟. 鞝滌稖鞚� 2025雲� 6鞗� 25鞚� 攴胳潣 氩曥爼 雽�毽澑 Brett A. Grimaud毳� 韱淀暣 鞕勲霅橃棃鞀惦媹雼�.

Rick E. Winningham, PDG et Directeur de Theravance Biopharma, a d茅clar茅 une transaction d鈥檌niti茅 importante le 23 juin 2025. Le dirigeant a effectu茅 un don authentique de 20 000 actions ordinaires sans aucune contrepartie financi猫re.

Apr猫s la transaction, les participations de Winningham comprennent :

  • 1 733 180 actions d茅tenues directement
  • 13 500 actions d茅tenues en qualit茅 de d茅positaire
  • 92 567 actions d茅tenues en fiducie

Le d茅p么t du formulaire 4 indique que Winningham conserve une participation importante dans la soci茅t茅 malgr茅 les actions donn茅es. La transaction a 茅t茅 r茅alis茅e dans des conditions normales et ne faisait pas partie d鈥檜n plan de trading selon la r猫gle 10b5-1. Le d茅p么t a 茅t茅 effectu茅 par son mandataire, Brett A. Grimaud, le 25 juin 2025.

Rick E. Winningham, CEO und Direktor von Theravance Biopharma, meldete am 23. Juni 2025 eine bedeutende Insider-Transaktion. Der Gesch盲ftsf眉hrer t盲tigte eine echte Schenkung von 20.000 Stammaktien ohne jegliche Gegenleistung.

Nach der Transaktion umfasst Winninghams Beteiligung:

  • 1.733.180 Aktien im Direktbesitz
  • 13.500 Aktien als Treuh盲nder gehalten
  • 92.567 Aktien in einem Trust gehalten

Die Form 4 Einreichung zeigt, dass Winningham trotz der geschenkten Aktien eine erhebliche Beteiligung am Unternehmen beh盲lt. Die Transaktion wurde unter regul盲ren Bedingungen durchgef眉hrt und war kein Teil eines Rule 10b5-1 Handelsplans. Die Einreichung erfolgte am 25. Juni 2025 durch seinen Bevollm盲chtigten Brett A. Grimaud.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Winningham Rick E
(Last) (First) (Middle)
C/O THERAVANCE BIOPHARMA US, LLC
901 GATEWAY BOULEVARD
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 06/23/2025 G 20,000(1) D $0 1,733,180 D
Ordinary Shares 13,500 I As Custodian
Ordinary Shares 92,567 I By Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Bona Fide Gift. No compensation was given to the donor for the gifting of shares.
/s/ Brett A. Grimaud, Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many TBPH shares did CEO Rick Winningham gift on June 23, 2025?

According to the Form 4 filing, CEO Rick Winningham gifted 20,000 ordinary shares on June 23, 2025 as a bona fide gift with no compensation received.

What is Rick Winningham's total direct ownership of TBPH shares after the reported transaction?

Following the reported transaction, Rick Winningham directly owns 1,733,180 ordinary shares of Theravance Biopharma (TBPH).

How many TBPH shares does Rick Winningham own indirectly?

Rick Winningham owns TBPH shares indirectly in two forms: 13,500 shares as a Custodian and 92,567 shares held in Trust, for a total indirect ownership of 106,067 shares.

What positions does Rick Winningham hold at TBPH?

According to the Form 4, Rick Winningham serves as both Director and Chief Executive Officer (CEO) of Theravance Biopharma, Inc.

What was the transaction price for TBPH shares in this Form 4 filing?

The transaction price was $0 as this was reported as a bona fide gift, with no compensation given to the donor for the gifting of shares.
Stock TBPH logo
Theravance Bioph

NASDAQ:TBPH

TBPH Rankings

#4415 Ranked by Market Cap
N/A Ranked by Dividends

TBPH Latest News

Jul 23, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
Jun 26, 2025
Theravance Biopharma Announces Approval of YUPELRI庐 (revefenacin) by China's NMPA
Jun 2, 2025
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
May 13, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
May 9, 2025
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

TBPH Latest SEC Filings

Jul 16, 2025
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity
Jul 14, 2025
[144] Theravance Biopharma, Inc. SEC Filing
Jun 26, 2025
[8-K] Theravance Biopharma, Inc. Reports Material Event

TBPH Stock Data

576.52M
47.65M
6.22%
93.64%
7.54%
Biotechnology
Pharmaceutical Preparations
United States
GEORGE TOWN, GRAND CAYMAN